Purchase Agreement



 Exhibit 10.20 
  
 PURCHASE AGREEMENT 
  
 THIS PURCHASE AGREEMENT (“Agreement”) is made as of the 19th day of July, 2005 by and among Tut Systems, Inc., a Delaware corporation (the “Company”), and the Investors set forth on the signature pages affixed hereto (each an “Investor” and
collectively the “Investors”). 
  
 Recitals

  
 A. The Company and the Investors are executing and
delivering this Agreement in reliance upon the exemption from securities registration afforded by the provisions of Regulation D (“Regulation D”), as promulgated by the U.S. Securities and Exchange Commission (the “SEC”) under
the Securities Act of 1933, as amended; and 
  
 B. The Investors
wish to purchase from the Company, and the Company wishes to sell and issue to the Investors, upon the terms and conditions stated in this Agreement, (i) an aggregate of 5,535,000 shares of the Company’s Common Stock, par value $0.001 per share
(together with any securities into which such shares may be reclassified the “Common Stock”), at a purchase price of $2.70 per share, and (ii) warrants to purchase an aggregate of 2,767,500 shares of Common Stock (subject to adjustment) at
an exercise price of $4.25 per share (subject to adjustment) in the form attached hereto as Exhibit A (the “Warrants”); and 
  
 C. Contemporaneous with the sale of the Common Stock and Warrants, the parties hereto will execute and deliver a Registration Rights Agreement, in the
form attached hereto as Exhibit B (the “Registration Rights Agreement”), pursuant to which the Company will agree to provide certain registration rights under the Securities Act of 1933, as amended, and the rules and regulations
promulgated thereunder, and applicable state securities laws. 
  
 In consideration of the mutual promises made herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 
  
 1. Definitions. In addition to those terms defined above and
elsewhere in this Agreement, for the purposes of this Agreement, the following terms shall have the meanings set forth below: 
  
 “Affiliate” means, with respect to any Person, any other Person which directly or indirectly through one or more intermediaries Controls,
is controlled by, or is under common control with, such Person. 
  
 “Business Day” means a day, other than a Saturday or Sunday, on which banks in New York City are open for the general transaction of business. 







 “Common Stock Equivalents” means any securities of the Company or the Subsidiaries which
would entitle the holder thereof to acquire at any time Common Stock, including without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exchangeable for, or otherwise
entitles the holder thereof to receive, Common Stock. 
  
 “Company’s Knowledge” means the actual knowledge of the executive officers (as defined in Rule 405 under the 1933 Act) of the Company, after due inquiry. 
  
 “Confidential Information” means trade secrets, confidential information and know-how (including but not
limited to ideas, formulae, compositions, processes, procedures and techniques, research and development information, computer program code, performance specifications, support documentation, drawings, specifications, designs, business and marketing
plans, and customer and supplier lists and related information). 
  
 “Control” (including the terms “controlling”, “controlled by” or “under common control with”) means the possession, direct or indirect, of the power to direct or cause the direction of the
management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise. 
  
 “Effective Date” means the date on which the initial Registration Statement is declared effective by the SEC. 
  
 “Effectiveness Deadline” means the date on which the initial
Registration Statement is required to be declared effective by the SEC under the terms of the Registration Rights Agreement. 
  
 “Intellectual Property” means all of the following: (i) patents, patent applications, patent disclosures and inventions (whether or not
patentable and whether or not reduced to practice); (ii) trademarks, service marks, trade dress, trade names, corporate names, logos, slogans and Internet domain names, together with all goodwill associated with each of the foregoing; (iii)
copyrights and copyrightable works; (iv) registrations, applications and renewals for any of the foregoing; and (v) proprietary computer software (including but not limited to data, data bases and documentation). 
  
 “Material Adverse Effect” means a material adverse effect on
(i) the assets, liabilities, results of operations, condition (financial or otherwise), business, or prospects of the Company and its Subsidiaries taken as a whole, or (ii) the ability of the Company to perform its obligations under the Transaction
Documents. 
  
 “Nasdaq” means The Nasdaq Stock
Market, Inc. 
  
 “Person” means an individual,
corporation, partnership, limited liability company, trust, business trust, association, joint stock company, joint venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically listed
herein. 
  

 -2- 








 “Purchase Price” means Fourteen Million Nine Hundred Forty-Four Thousand Five Hundred
Dollars ($14,944,500). 
  
 “Required Investors”
means the Investors purchasing a least a majority of the Shares issued on the Closing Date pursuant to this Agreement. 
  
 “SEC Filings” has the meaning set forth in Section 4.6. 
  
 “Registration Statement” has the meaning set forth in the Registration Rights Agreement. 
  
 “Securities” means the Shares, the Warrants and the Warrant
Shares. 
  
 “Shares” means the shares of Common
Stock being purchased by the Investors hereunder. 
  
 “Subsidiary” of any Person means another Person, an amount of the voting securities, other voting ownership or voting partnership interests of which is sufficient to elect at least a majority of its Board of Directors or
other governing body (or, if there are no such voting interests, 50% or more of the equity interests of which) is owned directly or indirectly by such first Person. 
  
 “Transaction Documents” means this Agreement, the Warrants and the Registration Rights Agreement.

  
 “Warrant Shares” means the shares of Common
Stock issuable upon the exercise of the Warrants. 
  
 “1933 Act” means the Securities Act of 1933, as amended, or any successor statute, and the rules and regulations promulgated thereunder. 
  
 “1934 Act” means the Securities Exchange Act of 1934, as amended, or any successor statute, and the rules
and regulations promulgated thereunder. 
  
 2. Purchase and
Sale of the Shares and Warrants. Subject to the terms and conditions of this Agreement, on the Closing Date, each of the Investors shall severally, and not jointly, purchase, and the Company shall sell and issue to each Investor, the Shares and
Warrants in the respective amounts set forth opposite each Investor’s name on the signature pages of this Agreement in exchange for the Purchase Price as specified in Section 3 below. 
  
 3. Closing. Upon confirmation that the other conditions to closing
specified herein have been satisfied or duly waived by the Investors, the Company shall deliver to Lowenstein Sandler PC, in trust, a certificate or certificates, registered in such name or names as the Investors may designate, representing the
Shares and Warrants, with instructions that such certificates are to be held for release to the Investors only upon payment in full of the Purchase 

  

 -3- 








 
Price to the Company by all the Investors. Upon such receipt by Lowenstein Sandler PC of the certificates, each Investor shall promptly, but no more than one
Business Day thereafter, cause a wire transfer in same day funds to be sent to the account of the Company as instructed in writing by the Company, in an amount representing such Investor’s pro rata portion of the Purchase Price as set forth on
the signature pages to this Agreement. On the date (the “Closing Date”) the Company receives the Purchase Price, the certificates evidencing the Shares and Warrants shall be released to the Investors (the “Closing”). The Closing
shall take place at the offices of Lowenstein Sandler PC, 1251 Avenue of the Americas, 18th Floor, New York, New York 10020, or at such other location and on such other date as the Company and the Investors shall mutually agree. 
  
 4. Representations and Warranties of the Company. The Company hereby
represents and warrants to each of the Investors that: 
  
 4. 1
Organization, Good Standing and Qualification. Each of the Company and its Subsidiaries is a corporation duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation and has all requisite
corporate power and authority to carry on its business as now conducted and to own its properties. Each of the Company and its Subsidiaries is duly qualified to do business as a foreign corporation and is in good standing in each jurisdiction in
which the conduct of its business or its ownership or leasing of property makes such qualification or leasing necessary unless the failure to so qualify has not had and could not reasonably be expected to have a Material Adverse Effect. The
Company’s Subsidiaries are as set forth in the SEC Filings. 
  
 4.2 Authorization. The Company has full power and authority and has taken all requisite action on the part of the Company, its officers, directors and stockholders necessary for (i) the authorization, execution and delivery of the
Transaction Documents, (ii) the authorization of the performance of all obligations of the Company hereunder or thereunder, and (iii) the authorization, issuance (or reservation for issuance) and delivery of the Securities. The Transaction
Documents, when delivered in accordance with the terms of this Agreement, will constitute the legal, valid and binding obligations of the Company, enforceable against the Company in accordance with their terms, except (i) as may be limited by (1)
applicable bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability, relating to or affecting creditors’ rights generally and (2) the effect of rules of law governing the availability of
equitable remedies and (ii) as rights to indemnity or contribution may be limited under federal or state securities laws or by principles of public policy thereunder. 
  
 4.3 Capitalization. The number of shares and type of all authorized, issued and outstanding capital stock, options
and other securities of the Company (whether or not presently convertible into or exercisable or exchangeable for shares of capital stock of the Company) is as set forth in the SEC Filings. All of the issued and outstanding shares of the
Company’s capital stock have been duly authorized and validly issued and are fully paid, nonassessable and free of pre-emptive rights and were issued in full compliance with applicable state and federal securities law and any rights of third
parties. Except as described in the SEC Filings, all of the issued and outstanding shares of capital stock of each Subsidiary have been 

  

 -4- 








 
duly authorized and validly issued and are fully paid, nonassessable and free of pre-emptive rights, were issued in full compliance with applicable state and
federal securities law and any rights of third parties and are owned by the Company, beneficially and of record, subject to no lien, encumbrance or other adverse claim. Except as described in the SEC Filings, no Person is entitled to pre-emptive or
similar statutory or contractual rights with respect to any securities of the Company. Except as described in the SEC Filings, there are no outstanding warrants, options, convertible securities or other rights, agreements or arrangements of any
character under which the Company or any of its Subsidiaries is or may be obligated to issue any equity securities of any kind and except as contemplated by this Agreement, neither the Company nor any of its Subsidiaries is currently in negotiations
for the issuance of any equity securities of any kind. Except as described in the SEC Filings and except for the Registration Rights Agreement, there are no voting agreements, buy-sell agreements, option or right of first purchase agreements or
other agreements of any kind among the Company and any of the securityholders of the Company relating to the securities of the Company held by them. Except as described in the SEC Filings and except as provided in the Registration Rights Agreement,
no Person has the right to require the Company to register any securities of the Company under the 1933 Act, whether on a demand basis or in connection with the registration of securities of the Company for its own account or for the account of any
other Person. 
  
 Except as described in the SEC Filings, the
issuance and sale of the Securities hereunder will not obligate the Company to issue shares of Common Stock or other securities to any other Person (other than the Investors) and will not result in the adjustment of the exercise, conversion,
exchange or reset price of any outstanding security. 
  
 Except as
described in the SEC Filings, the Company does not have outstanding stockholder purchase rights or “poison pill” or any similar arrangement in effect giving any Person the right to purchase any equity interest in the Company upon the
occurrence of certain events. 
  
 4.4 Valid Issuance. The
Shares have been duly and validly authorized and, when issued and paid for pursuant to this Agreement, will be validly issued, fully paid and nonassessable, and shall be free and clear of all encumbrances and restrictions (other than those created
by the Investors), except for restrictions on transfer set forth in the Transaction Documents or imposed by applicable securities laws. The Warrants have been duly and validly authorized. Upon the due exercise of the Warrants, the Warrant Shares
will be validly issued, fully paid and non-assessable free and clear of all encumbrances and restrictions, except for restrictions on transfer set forth in the Transaction Documents or imposed by applicable securities laws and except for those
created by the Investors. The Company has reserved a sufficient number of shares of Common Stock for issuance upon the exercise of the Warrants, free and clear of all encumbrances and restrictions, except for restrictions on transfer set forth in
the Transaction Documents or imposed by applicable securities laws and except for those created by the Investors. 
  
 4.5 Consents. The execution, delivery and performance by the Company of the Transaction Documents and the offer, issuance and sale of the
Securities require no consent of, action by or in respect of, or filing with, any Person, governmental body, agency, or official 

  

 -5- 








 
other than filings that have been made pursuant to applicable state securities laws and post-sale filings pursuant to applicable state and federal securities
laws which the Company undertakes to file within the applicable time periods. Subject to the accuracy of the representations and warranties of each Investor set forth in Section 5 hereof, the Company has taken all action necessary to exempt (i) the
issuance and sale of the Securities, (ii) the issuance of the Warrant Shares upon due exercise of the Warrants, and (iii) the other transactions contemplated by the Transaction Documents from the provisions of any stockholder rights plan or other
“poison pill” arrangement, any anti-takeover, business combination or control share law or statute binding on the Company or to which the Company or any of its assets and properties may be subject and any provision of the Company’s
Certificate of Incorporation or Bylaws that is or could reasonably be expected to become applicable to the Investors as a result of the transactions contemplated hereby, including without limitation, the issuance of the Securities and the ownership,
disposition or voting of the Securities, as applicable, by the Investors or the exercise of any right granted to the Investors pursuant to this Agreement or the other Transaction Documents. 
  
 4.6 Delivery of SEC Filings; Business. The Company has made available
to the Investors through the EDGAR system, true and complete copies of the Company’s most recent Annual Report on Form 10-K for the fiscal year ended December 31, 2004 (as amended as of the date hereof, the “10-K”), and all other
reports filed by the Company pursuant to the 1934 Act since the filing of the 10-K and prior to the date hereof (collectively, the “SEC Filings”). The SEC Filings are the only filings required of the Company pursuant to the 1934 Act for
such period. The Company and its Subsidiaries are engaged in all material respects only in the business described in the SEC Filings and the SEC Filings contain a complete and accurate description in all material respects of the business of the
Company and its Subsidiaries, taken as a whole. 
  
 4.7 Use of
Proceeds. The net proceeds of the sale of the Shares and the Warrants hereunder shall be used by the Company for working capital and general corporate purposes. 
  
 4.8 No Material Adverse Change. Since December 31, 2004, except as identified and described in the SEC Filings, there
has not been: 
  
 (i) any change in the consolidated assets,
liabilities, financial condition or operating results of the Company from that reflected in the financial statements included in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2005, except for changes in the
ordinary course of business which have not had and could not reasonably be expected to have a Material Adverse Effect, individually or in the aggregate; 
  
 (ii) any declaration or payment of any dividend, or any authorization or payment of any distribution, on any of the capital stock of the Company, or any
redemption or repurchase of any securities of the Company; 
  
 (iii) any material damage, destruction or loss, whether or not covered by insurance to any assets or properties of the Company or its Subsidiaries; 
  

 -6- 








 (iv) any waiver, not in the ordinary course of business, by the Company or any Subsidiary of a material
right or of a material debt owed to it; 
  
 (v) any satisfaction
or discharge of any lien, claim or encumbrance or payment of any obligation by the Company or a Subsidiary, except in the ordinary course of business and which is not material to the assets, properties, financial condition, operating results or
business of the Company and its Subsidiaries taken as a whole (as such business is presently conducted and as it is proposed to be conducted); 
  
 (vi) any change or amendment to the Company’s Certificate of Incorporation or Bylaws, or material change to any material contract or arrangement by
which the Company or any Subsidiary is bound or to which any of their respective assets or properties is subject; 
  
 (vii) any material labor difficulties or labor union organizing activities with respect to employees of the Company or any Subsidiary; 
  
 (viii) any material transaction entered into by the Company or a Subsidiary
other than in the ordinary course of business; 
  
 (ix) the loss
of the services of any key employee, or material change in the composition or duties of the senior management of the Company; 
  
 (x) the loss or threatened loss of any customer which has had or could reasonably be expected to have a Material Adverse Effect; or 
  
 (xi) any other event or condition of any character that has had or could
reasonably be expected to have a Material Adverse Effect. 
  
 4.9
SEC Filings; S-3 Eligibility. 
  
 (a) At the time of
filing thereof, the SEC Filings complied as to form in all material respects with the requirements of the 1934 Act and did not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the
statements made therein, in the light of the circumstances under which they were made, not misleading. 
  
 (b) Each registration statement and any amendment thereto filed by the Company since January 1, 2002 pursuant to the 1933 Act and the rules and
regulations thereunder, as of the date such statement or amendment became effective, complied as to form in all material respects with the 1933 Act and did not contain any untrue statement of a material fact or omit to state any material fact
required to be stated therein or necessary in order to make the statements made therein not misleading; and each prospectus filed pursuant to Rule 424(b) under the 1933 Act, as of its issue date and as of the closing of any sale of securities
pursuant thereto did not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the statements made therein, in the light of the circumstances under which they
were made, not misleading. 
  

 -7- 








 (c) The Company is eligible to use Form S-3 to register the Registrable Securities (as such term is
defined in the Registration Rights Agreement) for sale by the Investors as contemplated by the Registration Rights Agreement. 
  
 4.10 No Conflict, Breach, Violation or Default. The execution, delivery and performance of the Transaction Documents by the Company and the
issuance and sale of the Securities will not conflict with or result in a breach or violation of any of the terms and provisions of, or constitute a default under (i) the Company’s Certificate of Incorporation or the Company’s Bylaws, both
as in effect on the date hereof (true and complete copies of which have been made available to the Investors through the EDGAR system), or (ii)(a) any statute, rule, regulation or order of any governmental agency or body or any court, domestic or
foreign, having jurisdiction over the Company, any Subsidiary or any of their respective assets or properties, or (b) any agreement or instrument to which the Company or any Subsidiary is a party or by which the Company or a Subsidiary is bound or
to which any of their respective assets or properties is subject. 
  
 4.11 Tax Matters. The Company and each Subsidiary has timely prepared and filed all tax returns required to have been filed by the Company or such Subsidiary with all appropriate governmental agencies and timely paid all taxes shown
thereon or otherwise owed by it, except where the failure to do so would not cause a Material Adverse Effect. The charges, accruals and reserves on the books of the Company in respect of taxes for all fiscal periods are adequate in all material
respects, and there are no material unpaid assessments against the Company or any Subsidiary nor, to the Company’s Knowledge, any basis for the assessment of any additional taxes, penalties or interest for any fiscal period or audits by any
federal, state or local taxing authority except for any assessment which is not material to the Company and its Subsidiaries, taken as a whole. All taxes and other assessments and levies that the Company or any Subsidiary is required to withhold or
to collect for payment have been duly withheld and collected and paid to the proper governmental entity or third party when due, except where the failure to do so would not cause a Material Adverse Effect. There are no tax liens or claims pending
or, to the Company’s Knowledge, threatened against the Company or any Subsidiary or any of their respective assets or property. There are no outstanding tax sharing agreements or other such arrangements between the Company and any Subsidiary or
other corporation or entity. 
  
 4.12 Title to Properties.
Except as disclosed in the SEC Filings, the Company and each Subsidiary has good and marketable title to all real properties and all other properties and assets owned by it, in each case free from liens, encumbrances and defects that would
materially affect the value thereof or materially interfere with the use made or currently planned to be made thereof by them; and except as disclosed in the SEC Filings, the Company and each Subsidiary holds any leased real or personal property
under valid and enforceable leases with no exceptions that would materially interfere with the use made or currently planned to be made thereof by them. 
  

 -8- 








 4.13 Certificates, Authorities and Permits. The Company and each Subsidiary possess adequate
certificates, authorities or permits issued by appropriate governmental agencies or bodies necessary to conduct the business now operated by it, except where the failure to do so would not cause a Material Adverse Effect, and, to the Company’s
Knowledge, neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification of any such certificate, authority or permit that, if determined adversely to the Company or such Subsidiary, could
reasonably be expected to have a Material Adverse Effect, individually or in the aggregate. 
  
 4.14 Labor Matters. 
  
 (a) The Company is not a party to or bound by any collective bargaining agreements or other agreements with labor organizations. The Company has not violated in any material respect any laws, regulations, orders or contract terms, affecting
the collective bargaining rights of employees, labor organizations or any laws, regulations or orders affecting employment discrimination, equal opportunity employment, or employees’ health, safety, welfare, wages and hours. 
  
 (b) (i) There are no labor disputes existing, or to the Company’s
Knowledge, threatened, involving strikes, slow-downs, work stoppages, job actions, disputes, lockouts or any other disruptions of or by the Company’s employees, (ii) there are no unfair labor practices or petitions for election pending or, to
the Company’s Knowledge, threatened before the National Labor Relations Board or any other federal, state or local labor commission relating to the Company’s employees, (iii) no demand for recognition or certification heretofore made by
any labor organization or group of employees is pending with respect to the Company and (iv) to the Company’s Knowledge, the Company enjoys good labor and employee relations with its employees and labor organizations. 
  
 (c) The Company is, and at all times has been, in compliance in all material
respects with all applicable laws respecting employment (including laws relating to classification of employees and independent contractors) and employment practices, terms and conditions of employment, wages and hours, and immigration and
naturalization. There are no claims pending against the Company before the Equal Employment Opportunity Commission or any other administrative body or in any court asserting any violation of Title VII of the Civil Rights Act of 1964, the Age
Discrimination Act of 1967, 42 U.S.C. §§ 1981 or 1983 or any other federal, state or local Law, statute or ordinance barring discrimination in employment. 
  
 (d) Except as disclosed in the SEC Filings, the Company is not a party to, or bound by, any employment or other contract or
agreement that contains any severance, termination pay or change of control liability or obligation, including, without limitation, any “excess parachute payment,” as defined in Section 2806(b) of the Internal Revenue Code. 
  
 (e) Each of the Company’s employees is a Person who is either a United
States citizen or a permanent resident entitled to work in the United States. To the Company’s Knowledge, the Company has no liability for the improper classification by the Company of such employees as independent contractors or leased
employees prior to the Closing. 
  

 -9- 








 4.15 Intellectual Property. 
  
 (a) All Intellectual Property of the Company and its Subsidiaries is currently in compliance in all material respects with
all legal requirements (including timely filings, proofs and payments of fees) and is, to the Company’s Knowledge, valid and enforceable. No Intellectual Property of the Company or its Subsidiaries which is necessary for the conduct of
Company’s and each of its Subsidiaries’ respective businesses as currently conducted or as currently proposed to be conducted has been or is now involved in any cancellation, dispute or litigation, and, to the Company’s Knowledge, no
such action is threatened. No patent of the Company or its Subsidiaries has been or is now involved in any interference, reissue, re-examination or opposition proceeding. 
  
 (b) All of the licenses and sublicenses and consent, royalty or other agreements concerning Intellectual Property which are
necessary for the conduct of the Company’s and each of its Subsidiaries’ respective businesses as currently conducted or as currently proposed to be conducted to which the Company or any Subsidiary is a party or by which any of their
assets are bound (other than generally commercially available, non-custom, off-the-shelf software application programs having a retail acquisition price of less than $10,000 per license) (collectively, “License Agreements”) are valid and
binding obligations of the Company or its Subsidiaries that are parties thereto and, to the Company’s Knowledge, the other parties thereto, enforceable in accordance with their terms, except to the extent that enforcement thereof may be limited
by bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance or other similar laws affecting the enforcement of creditors’ rights generally, and there exists no event or condition which will result in a material violation or
breach of or constitute (with or without due notice or lapse of time or both) a default by the Company or any of its Subsidiaries under any such License Agreement. 
  
 (c) The Company and its Subsidiaries own or have the valid right to use all of the Intellectual Property that is necessary
for the conduct of the Company’s and each of its Subsidiaries’ respective businesses as currently conducted or as currently proposed to be conducted and for the ownership, maintenance and operation of the Company’s and its
Subsidiaries’ properties and assets, free and clear of all liens, encumbrances, adverse claims or obligations to license all such owned Intellectual Property and Confidential Information, other than licenses entered into in the ordinary course
of the Company’s and its Subsidiaries’ businesses. The Company or a Subsidiary has a valid and enforceable right to use all third party Intellectual Property and Confidential Information used or held for use in the respective businesses of
the Company and its Subsidiaries, except to the extent that enforcement thereof may be limited by bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance or other similar laws affecting the enforcement of creditors’ rights
generally. 
  
 (d) To the Company’s Knowledge, the conduct
of the Company’s and its Subsidiaries’ businesses as currently conducted does not infringe or otherwise impair or conflict with (collectively, “Infringe”) any Intellectual Property rights of any third party or any 

  

 -10- 








 
confidentiality obligation owed to a third party, the Intellectual Property and Confidential Information of the Company and its Subsidiaries which are
necessary for the conduct of Company’s and each of its Subsidiaries’ respective businesses as currently conducted or as currently proposed to be conducted are not being Infringed by any third party in any material respect. There is no
litigation or order pending or outstanding or, to the Company’s Knowledge, threatened claim, that seeks to limit or challenge or that concerns the ownership, use, validity or enforceability of any Intellectual Property or Confidential
Information of the Company and its Subsidiaries and the Company’s and its Subsidiaries’ use of any Intellectual Property or Confidential Information owned by a third party, and, to the Company’s Knowledge, there is no valid basis for
the same. 
  
 (e) The consummation of the transactions
contemplated hereby and by the other Transaction Documents will not result in the alteration, loss, impairment of or restriction on the Company’s or any of its Subsidiaries’ ownership or right to use any of the Intellectual Property or
Confidential Information which is necessary for the conduct of Company’s and each of its Subsidiaries’ respective businesses as currently conducted or as currently proposed to be conducted. 
  
 (f) The Company and its Subsidiaries have taken reasonable steps to protect
the Company’s and its Subsidiaries’ rights in their Intellectual Property and Confidential Information. Each employee, consultant and contractor who has had access to Confidential Information which is necessary for the conduct of
Company’s and each of its Subsidiaries’ respective businesses as currently conducted or as currently proposed to be conducted has executed an agreement to maintain the confidentiality of such Confidential Information and has executed
appropriate agreements that are substantially consistent with the Company’s standard forms thereof. Except under confidentiality obligations, there has been no material disclosure of any of the Company’s or its Subsidiaries’
Confidential Information to any third party. 
  
 4.16
Environmental Matters. Neither the Company nor any Subsidiary is in violation of any statute, rule, regulation, decision or order of any governmental agency or body or any court, domestic or foreign, relating to the use, disposal or release
of hazardous or toxic substances or relating to the protection or restoration of the environment or human exposure to hazardous or toxic substances (collectively, “Environmental Laws”), owns or operates any real property contaminated with
any substance that is subject to any Environmental Laws, is liable for any off-site disposal or contamination pursuant to any Environmental Laws, or is subject to any claim relating to any Environmental Laws, which violation, contamination,
liability or claim has had or could reasonably be expected to have a Material Adverse Effect, individually or in the aggregate; and there is no pending or, to the Company’s Knowledge, threatened investigation that might lead to such a claim.

  
 4.17 Litigation. Except as described in the SEC
Filings, there are no pending material actions, suits or proceedings against or affecting the Company, its Subsidiaries or any of its or their properties; and to the Company’s Knowledge, no such actions, suits or proceedings are threatened or
contemplated. 
  

 -11- 








 4.18 Financial Statements. The financial statements included in each SEC Filing present fairly, in
all material respects, the consolidated financial position of the Company as of the dates shown and its consolidated results of operations and cash flows for the periods shown, and such financial statements have been prepared in conformity with
United States generally accepted accounting principles applied on a consistent basis (“GAAP”) (except as may be disclosed therein or in the notes thereto, and, in the case of quarterly financial statements, as permitted by Form 10-Q under
the 1934 Act). Except as set forth in the financial statements of the Company included in the SEC Filings filed prior to the date hereof, neither the Company nor any of its Subsidiaries has incurred any liabilities, contingent or otherwise, except
those incurred in the ordinary course of business, consistent (as to amount and nature) with past practices since the date of such financial statements, none of which, individually or in the aggregate, have had or could reasonably be expected to
have a Material Adverse Effect. 
  
 4.19 Insurance
Coverage. The Company and each Subsidiary maintains in full force and effect insurance coverage that is customary for comparably situated companies for the business being conducted and properties owned or leased by the Company and each
Subsidiary, and the Company reasonably believes such insurance coverage to be adequate against all liabilities, claims and risks against which it is customary for comparably situated companies to insure. 
  
 4.20 Compliance with Nasdaq Continued Listing Requirements. The
Company is in compliance with applicable Nasdaq continued listing requirements. There are no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of the Common Stock on Nasdaq and
the Company has not received any notice of, nor to the Company’s Knowledge is there any basis for, the delisting of the Common Stock from Nasdaq. 
  
 4.21 Brokers and Finders. No Person will have, as a result of the transactions contemplated by the Transaction Documents, any valid right, interest
or claim against or upon the Company, any Subsidiary or an Investor for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of the Company, other than as previously disclosed
to the Investors in writing. 
  
 4.22 No Directed Selling
Efforts or General Solicitation. Neither the Company nor any Person acting on its behalf has conducted any general solicitation or general advertising (as those terms are used in Regulation D) in connection with the offer or sale of any of the
Securities. 
  
 4.23 No Integrated Offering. Neither the
Company nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any Company security or solicited any offers to buy any security, under circumstances that would adversely
affect reliance by the Company on Section 4(2) for the exemption from registration for the transactions contemplated hereby or would require registration of the Securities under the 1933 Act. 
  

 -12- 








 4.24 Private Placement. Assuming the accuracy of the representations of the Investors in Section
5, the offer and sale of the Securities to the Investors as contemplated hereby is exempt from the registration requirements of the 1933 Act. 
  
 4.25 Questionable Payments. Neither the Company nor any of its Subsidiaries nor, to the Company’s Knowledge, any of their
respective current or former stockholders, directors, officers, employees, agents or other Persons acting on behalf of the Company or any Subsidiary, has on behalf of the Company or any Subsidiary or in connection with their respective businesses:
(a) used any corporate funds for unlawful contributions, gifts, entertainment or other unlawful expenses relating to political activity; (b) made any direct or indirect unlawful payments to any governmental officials or employees from corporate
funds; (c) established or maintained any unlawful or unrecorded fund of corporate monies or other assets; (d) made any false or fictitious entries on the books and records of the Company or any Subsidiary; or (e) made any unlawful bribe, rebate,
payoff, influence payment, kickback or other unlawful payment of any nature. 
  
 4.26 Transactions with Affiliates. Except as disclosed in the SEC Filings, none of the officers or directors of the Company and, to the Company’s Knowledge, none of the employees of the Company is
presently a party to any transaction with the Company or any Subsidiary (other than as holders of stock options and/or warrants, and for services as employees, officers and directors), including any contract, agreement or other arrangement providing
for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any officer, director or such employee or, to the Company’s Knowledge, any entity in which any
officer, director, or any such employee has a substantial interest or is an officer, director, trustee or partner. 
  
 4.27 Internal Controls. The Company is in material compliance with the provisions of the Sarbanes-Oxley Act of 2002 currently applicable to the
Company. The Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations, (ii)
transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management’s general or specific
authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. The Company has established disclosure controls and
procedures (as defined in 1934 Act Rules 13a-14 and 15d-14) for the Company and designed such disclosure controls and procedures to ensure that material information relating to the Company, including the Subsidiaries, is made known to the certifying
officers by others within those entities, particularly during the period in which the Company’s most recently filed period report under the 1934 Act, as the case may be, is being prepared. The Company’s certifying officers have evaluated
the effectiveness of the Company’s controls and procedures as of the end of the period covered by the most recently filed periodic report under the 1934 Act (such date, the “Evaluation Date”). The Company presented in its most
recently filed periodic report under the 1934 Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, 

  

 -13- 








 
there have been no significant changes in the Company’s internal controls (as such term is defined in Item 308 of Regulation S-K) or, to the
Company’s Knowledge, in other factors that could significantly affect the Company’s internal controls. The Company maintains and will continue to maintain a standard system of accounting established and administered in accordance with GAAP
and the applicable requirements of the 1934 Act. 
  
 4.28
Disclosures. Neither the Company nor any Person acting on its behalf has provided the Investors or their agents or counsel with any information that constitutes or might constitute material, non-public information. The written materials
delivered to the Investors in connection with the transactions contemplated by the Transaction Documents do not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements contained
therein, in light of the circumstances under which they were made, not misleading. 
  
 5. Representations and Warranties of the Investors. Each of the Investors hereby severally, and not jointly, represents and warrants to the Company that: 
  
 5.1 Organization and Existence. Such Investor is a validly existing
corporation, limited partnership or limited liability company and has all requisite corporate, partnership or limited liability company power and authority to invest in the Securities pursuant to this Agreement. 
  
 5.2 Authorization. The execution, delivery and performance by such
Investor of the Transaction Documents to which such Investor is a party have been duly authorized and will each constitute the valid and legally binding obligation of such Investor, enforceable against such Investor in accordance with their
respective terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability, relating to or affecting creditors’ rights generally. 
  
 5.3 Purchase Entirely for Own Account. The Securities to be received
by such Investor hereunder will be acquired for such Investor’s own account, not as nominee or agent, and not with a view to the resale or distribution of any part thereof in violation of the 1933 Act, and such Investor has no present intention
of selling, granting any participation in, or otherwise distributing the same in violation of the 1933 Act without prejudice, however, to such Investor’s right at all times to sell or otherwise dispose of all or any part of such Securities in
compliance with applicable federal and state securities laws. Nothing contained herein shall be deemed a representation or warranty by such Investor to hold the Securities for any period of time. Such Investor is not a broker-dealer
registered with the SEC under the 1934 Act or an entity engaged in a business that would require it to be so registered. 
  
 5.4 Investment Experience. Such Investor acknowledges that it can bear the economic risk and complete loss of its investment in the Securities and
has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment contemplated hereby. 
  

 -14- 








 5.5 Disclosure of Information. Such Investor has had an opportunity to receive all information
related to the Company requested by it and to ask questions of and receive answers from the Company regarding the Company, its business and the terms and conditions of the offering of the Securities. Such Investor acknowledges receipt of copies of
the SEC Filings. Neither such inquiries nor any other due diligence investigation conducted by such Investor shall modify, amend or affect such Investor’s right to rely on the Company’s representations and warranties contained in this
Agreement. 
  
 5.6 Restricted Securities. Such Investor
understands that the Securities are characterized as “restricted securities” under the U.S. federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under such
laws and applicable regulations such securities may be resold without registration under the 1933 Act only in certain limited circumstances. 
  
 5.7 Legends. It is understood that, except as provided below, certificates evidencing the Securities may bear the following or any similar legend:

  
 (a) “The securities represented hereby may not be
transferred unless (i) such securities have been registered for sale pursuant to the Securities Act of 1933, as amended, (ii) such securities may be sold pursuant to Rule 144(k), or (iii) the Company has received an opinion of counsel reasonably
satisfactory to it that such transfer may lawfully be made without registration under the Securities Act of 1933 or qualification under applicable state securities laws.” 
  
 (b) If required by the authorities of any state in connection with the issuance of sale of the Securities, the legend
required by such state authority. 
  
 5.8 Accredited
Investor. Such Investor is an accredited investor as defined in Rule 501(a) of Regulation D, as amended, under the 1933 Act. 
  
 5.9 No General Solicitation. Such Investor did not learn of the investment in the Securities as a result of any public advertising or general
solicitation. 
  
 5.10 Brokers and Finders. No Person will
have, as a result of the transactions contemplated by the Transaction Documents, any valid right, interest or claim against or upon the Company, any Subsidiary or an Investor for any commission, fee or other compensation pursuant to any agreement,
arrangement or understanding entered into by or on behalf of such Investor. 
  
 5.11 Prohibited Transactions. During the last thirty (30) days prior to the date hereof, neither such Investor nor any Affiliate of such Investor which (x) had knowledge of the transactions contemplated hereby,
(y) has or shares discretion relating to such Investor’s investments or trading or information concerning such Investor’s investments, including in respect of the Securities, or (z) is subject to such Investor’s review or input
concerning such Affiliate’s investments or trading (collectively, “Trading Affiliates”) has, directly or indirectly, effected or agreed to effect any short sale, whether or not against the box, established any “put 

  

 -15- 








 
equivalent position” (as defined in Rule 16a-1(h) under the 1934 Act) with respect to the Common Stock, granted any other right (including, without
limitation, any put or call option) with respect to the Common Stock or with respect to any security that includes, relates to or derived any significant part of its value from the Common Stock or otherwise sought to hedge its position in the
Securities (each, a “Prohibited Transaction”). Prior to the earliest to occur of (i) the termination of this Agreement, (ii) the Effective Date or (iii) the Effectiveness Deadline, such Investor shall not, and shall cause its Trading
Affiliates not to, engage, directly or indirectly, in a Prohibited Transaction. Such Investor acknowledges that the representations, warranties and covenants contained in this Section 5.11 are being made for the benefit of the Investors as well as
the Company and that each of the other Investors shall have an independent right to assert any claims against such Investor arising out of any breach or violation of the provisions of this Section 5.11. 
  
 6. Conditions to Closing. 
  
 6.1 Conditions to the Investors’ Obligations. The obligation of
each Investor to purchase the Shares and the Warrants at the Closing is subject to the fulfillment to such Investor’s satisfaction, on or prior to the Closing Date, of the following conditions, any of which may be waived by such Investor (as to
itself only): 
  
 (a) The representations and warranties made by
the Company in Section 4 hereof qualified as to materiality shall be true and correct at all times prior to and on the Closing Date, except to the extent any such representation or warranty expressly speaks as of an earlier date, in which case such
representation or warranty shall be true and correct as of such earlier date, and, the representations and warranties made by the Company in Section 4 hereof not qualified as to materiality shall be true and correct in all material respects at all
times prior to and on the Closing Date, except to the extent any such representation or warranty expressly speaks as of an earlier date, in which case such representation or warranty shall be true and correct in all material respects as of such
earlier date. The Company shall have performed in all material respects all obligations and covenants herein required to be performed by it on or prior to the Closing Date. 
  
 (b) The Company shall have obtained any and all consents, permits, approvals, registrations and waivers necessary or
appropriate for consummation of the purchase and sale of the Securities and the consummation of the other transactions contemplated by the Transaction Documents, all of which shall be in full force and effect. 
  
 (c) The Company shall have executed and delivered the Registration Rights
Agreement. 
  
 (d) The Company shall have received confirmation
from Nasdaq to the effect that (i) the issuance and sale of the Securities as contemplated hereby will not require stockholder approval pursuant to the requirements of Nasdaq Marketplace Rule 4350(i), and (ii) that the Shares and the Warrant Shares
have been approved for inclusion in The Nasdaq National Market System upon official notice of issuance. 
  

 -16- 








 (e) No judgment, writ, order, injunction, award or decree of or by any court, or judge, justice or
magistrate, including any bankruptcy court or judge, or any order of or by any governmental authority, shall have been issued, and no action or proceeding shall have been instituted by any governmental authority, enjoining or preventing the
consummation of the transactions contemplated hereby or in the other Transaction Documents. 
  
 (f) The Company shall have delivered a Certificate, executed on behalf of the Company by its Chief Executive Officer or its Chief Financial Officer, dated as of the Closing Date, certifying to the fulfillment of the
conditions specified in subsections (a), (b), (d), (e) and (i) of this Section 6.1. 
  
 (g) The Company shall have delivered a Certificate, executed on behalf of the Company by its Secretary, dated as of the Closing Date, certifying the resolutions adopted by the Board of Directors of the Company
approving the transactions contemplated by this Agreement and the other Transaction Documents and the issuance of the Securities, certifying the current versions of the Certificate of Incorporation and Bylaws of the Company and certifying as to the
signatures and authority of persons signing the Transaction Documents and related documents on behalf of the Company. 
  
 (h) The Investors shall have received an opinion from DLA Piper Rudnick Gray Cary US LLP, the Company’s counsel, dated as of the Closing Date, in
form and substance reasonably acceptable to the Investors and addressing such legal matters as the Investors may reasonably request. 
  
 (i) No stop order or suspension of trading shall have been imposed by Nasdaq, the SEC or any other governmental or regulatory body with respect to public
trading in the Common Stock. 
  
 6.2 Conditions to Obligations
of the Company. The Company’s obligation to sell and issue the Shares and the Warrants at the Closing is subject to the fulfillment to the satisfaction of the Company on or prior to the Closing Date of the following conditions, any of which
may be waived by the Company: 
  
 (a) The representations and
warranties made by the Investors in Section 5 hereof, other than the representations and warranties contained in Sections 5.3, 5.4, 5.5, 5.6, 5.7, 5.8 and 5.9 (the “Investment Representations”), shall be true and correct in all material
respects when made, and shall be true and correct in all material respects on the Closing Date with the same force and effect as if they had been made on and as of said date. The Investment Representations shall be true and correct in all respects
when made, and shall be true and correct in all respects on the Closing Date with the same force and effect as if they had been made on and as of said date. The Investors shall have performed in all material respects all obligations and covenants
herein required to be performed by them on or prior to the Closing Date. 
  
 (b) The Investors shall have executed and delivered the Registration Rights Agreement. 
  

 -17- 








 (c) The Investors shall have delivered the Purchase Price to the Company. 
  
 (d) The Company shall have received confirmation from Nasdaq to the effect
that (i) the issuance and sale of the Securities as contemplated hereby will not require stockholder approval pursuant to the requirements of Nasdaq Marketplace Rule 4350(i), and (ii) that the Shares and the Warrant Shares have been approved for
inclusion in The Nasdaq National Market System upon official notice of issuance. 
  
 6.3 Termination of Obligations to Effect Closing; Effects. 
  
 (a) The obligations of the Company, on the one hand, and the Investors, on the other hand, to effect the Closing shall terminate as follows: 

 
 (i) Upon the mutual written consent of the Company and the Investors;

  
 (ii) By the Company if any of the conditions set forth in
Section 6.2 shall have become incapable of fulfillment, and shall not have been waived by the Company; 
  
 (iii) By an Investor (with respect to itself only) if any of the conditions set forth in Section 6.1 shall have become incapable of fulfillment, and
shall not have been waived by the Investor; or 
  
 (iv) By either
the Company or any Investor (with respect to itself only) if the Closing has not occurred on or prior to August 15, 2005; 
  
 provided, however, that, except in the case of clause (i) above, the party seeking to terminate its obligation to effect the Closing shall not then be in breach of any of
its representations, warranties, covenants or agreements contained in this Agreement or the other Transaction Documents if such breach has resulted in the circumstances giving rise to such party’s seeking to terminate its obligation to effect
the Closing. 
  
 (b) In the event of termination by the Company
or any Investor of its obligations to effect the Closing pursuant to this Section 6.3, written notice thereof shall forthwith be given to the other Investors and the other Investors shall have the right to terminate their obligations to effect the
Closing upon written notice to the Company and the other Investors. Nothing in this Section 6.3 shall be deemed to release any party from any liability for any breach by such party of the terms and provisions of this Agreement or the other
Transaction Documents or to impair the right of any party to compel specific performance by any other party of its obligations under this Agreement or the other Transaction Documents. 
  

 -18- 








 7. Covenants and Agreements of the Company. 
  
 7.1 Reservation of Common Stock. The Company shall at all times
reserve and keep available out of its authorized but unissued shares of Common Stock, solely for the purpose of providing for the exercise of the Warrants, such number of shares of Common Stock as shall from time to time equal the number of shares
sufficient to permit the exercise of the Warrants issued pursuant to this Agreement in accordance with their respective terms. 
  
 7.2 Reports. The Company will furnish to the Investors and/or their assignees such information relating to the Company and its Subsidiaries as from
time to time may reasonably be requested by the Investors and/or their assignees; provided, however, that the Company shall not disclose material nonpublic information to the Investors, or to advisors to or representatives of the Investors, unless
prior to disclosure of such information the Company identifies such information as being material nonpublic information and provides the Investors, such advisors and representatives with the opportunity to accept or refuse to accept such material
nonpublic information for review and any Investor wishing to obtain such information enters into an appropriate confidentiality agreement with the Company with respect thereto. 
  
 7.3 No Conflicting Agreements. The Company will not take any action, enter into any agreement or make any commitment
that would conflict or interfere in any material respect with the Company’s obligations to the Investors under the Transaction Documents. 
  
 7.4 Insurance. The Company shall not materially reduce the insurance coverages described in Section 4.19. 
  
 7.5 Compliance with Laws. The Company will comply in all material
respects with all applicable laws, rules, regulations, orders and decrees of all governmental authorities. 
  
 7.6 Listing of Underlying Shares and Related Matters. Promptly following the date hereof, the Company shall take all necessary action to cause the
Shares and the Warrant Shares to be listed on the Nasdaq National Market System no later than the Closing Date. Further, if the Company applies to have its Common Stock or other securities traded on any other principal stock exchange or market, it
shall include in such application the Shares and the Warrant Shares and will take such other action as is necessary to cause such Common Stock to be so listed. The Company will use commercially reasonable efforts to continue the listing and trading
of its Common Stock on the Nasdaq National Market System and, in accordance, therewith, will use commercially reasonable efforts to comply in all respects with the Company’s reporting, filing and other obligations under the bylaws or rules of
such market or exchange, as applicable. 
  
 7.7 Termination of
Covenants. The provisions of Sections 7.2 through 7.5 shall terminate and be of no further force and effect on the date on which the Company’s obligations under the Registration Rights Agreement to register or maintain the effectiveness of
any registration covering the Registrable Securities (as such term is defined in the Registration Rights Agreement) shall terminate. 
  

 -19- 








 7.8 Removal of Legends. Upon the earlier of (i) registration for resale pursuant to the
Registration Rights Agreement and receipt by the Company of the Investor’s written confirmation that such Securities will not be disposed of except in compliance with the prospectus delivery requirements of the 1933 Act or (ii) Rule 144(k)
becoming available the Company shall, upon an Investor’s written request, promptly cause certificates evidencing the Investor’s Securities to be replaced with certificates which do not bear such restrictive legends, and Warrant Shares
subsequently issued upon due exercise of the Warrants shall not bear such restrictive legends provided the provisions of either clause (i) or clause (ii) above, as applicable, are satisfied with respect to such Warrant Shares. When the Company is
required to cause unlegended certificates to replace previously issued legended certificates, if unlegended certificates are not delivered to an Investor within three (3) Business Days of submission by that Investor of legended certificate(s) to the
Company’s transfer agent together with a representation letter in customary form, the Company shall be liable to the Investor for liquidated damages in an amount equal to 1.5% of the aggregate purchase price of the Securities evidenced by such
certificate(s) for each thirty (30) day period (or portion thereof) beyond such three (3) Business Day that the unlegended certificates have not been so delivered. 
  
 7.9 Purchase Price Adjustments. 
  
 (a) If during the one-year period commencing on the Closing Date and ending on the first anniversary of the Closing Date
(the “Adjustment Period”), the Company issues or sells any shares of its Common Stock in a capital raising transaction to one or more institutional investors at a Per Share Selling Price (as defined below) lower than $2.70 (appropriately
adjusted for any stock split, reverse stock split, stock dividend or other reclassification or combination of the Common Stock occurring after the Closing Date) (the “Per Share Purchase Price”), the Per Share Purchase Price of the Shares
sold to the Investors hereunder shall be adjusted downward to equal such lower Per Share Selling Price and the Investors shall be entitled to receive additional shares of Common Stock as provided in Section 7.9(c). The Company shall give to the
Investors written notice of any such issuance or sale within 24 hours of the closing of the related capital raising transaction. The term “Shares” as used in this Agreement shall include any shares issued to the Investors pursuant to this
Section 7.9. This Section 7.9 shall not apply to the Company’s issuance of shares of its Common Stock in a merger, acquisition, or other similar transaction. 
  
 (b) (i) For the purposes of this Section 7.9, the term “Per Share Selling Price” shall include the amount
actually paid by third parties for each share of Common Stock without deduction of any expenses incurred or any underwriting commissions or concessions paid or allowed by the Company in connection therewith. A sale of shares of Common Stock shall
include the sale or issuance of Common Stock Equivalents under which the Company is or may become obligated to issue shares of Common Stock, and in such circumstances the Per Share Selling Price of the Common Stock covered thereby shall also include
the exercise or conversion price thereof (in addition to the consideration received by the Company upon such sale or issuance). In case of any such security issued in a “Variable Rate Transaction” or an “MFN Transaction” (each as
defined below), the Per Share Selling Price shall be deemed to be the lowest conversion or exercise price in effect at any time during the Adjustment Period in the case of a Variable Rate Transaction, or the lowest adjustment price in 

  

 -20- 








 
effect at any time during the Adjustment Period in the case of an MFN Transaction (regardless of whether shares of Common Stock are actually issued at such
price). If an adjustment is made in accordance with the preceding sentence and the relevant conversion, exercise or adjustment price is subsequently reduced at any time during the Adjustment Period below the price in effect at the time such
adjustment was made, further adjustments shall be made pursuant hereto to reflect any such subsequent reductions. 
  
 (ii) The term “Variable Rate Transaction” shall mean a transaction in which the Company issues or sells (a) Common Stock Equivalents either (x)
at a conversion, exercise or exchange rate or other price that is based upon and/or varies with the trading prices of or quotations for the Common Stock at any time after the initial issuance of such debt or equity securities, or (y) with a fixed
conversion, exercise or exchange price that is subject to being adjusted at some future date after the initial issuance of such debt or equity security or upon the occurrence of specified or contingent events directly or indirectly related to the
business of the Company or the market for the Common Stock (but excluding standard stock split anti-dilution provisions), or (b) any securities of the Company pursuant to an “equity line” structure which provides for the sale, from time to
time, of securities of the Company which are registered for resale pursuant to the 1933 Act. 
  
 (iii) The term “MFN Transaction” shall mean a transaction in which the Company issues or sells any securities in a capital raising transaction or series of related transactions (the “New Offering”)
which grants to the investor (the “New Investor”) the right to receive additional securities based upon future capital raising transactions of the Company on terms more favorable than those granted to the New Investor in the New Offering.

  
 (c) If an adjustment of the Per Share Purchase Price is
required pursuant to Section 7.9(a), to effect such adjustment the Company shall deliver to each Investor within twenty (20) calendar days of the closing of the transaction giving rise to the adjustment (“Delivery Date”) additional newly
issued, fully paid and nonassessable shares of Common Stock in an amount equal to (i) the aggregate Purchase Price paid by the Investor divided by the Per Share Selling Price determined under Section 7.9(a), minus (ii) the total number of shares of
Common Stock originally purchased by that Investor hereunder; provided, however, that if at the time of the closing of the transaction giving rise to the adjustment, the Investor and its assignees hereunder collectively own less than all of the
Shares originally purchased by the Investor hereunder, the additional shares to be delivered pursuant to this adjustment shall be pro rated by a fraction, the numerator of which is the number of original Shares owned by the Investor and such
assignees at the time of the closing of the transaction giving rise to the adjustment and the denominator of which is the total number of Shares originally purchased by the Investor hereunder, and; provided, further, that for purposes of calculating
any such adjustment, the Investor or an assignee shall be deemed to have sold a number of Shares equal to any short position in the Common Stock maintained by the Investor or any such assignee, as the case may be, at the time of the transaction
giving rise to the adjustment. In the event the Company fails to deliver the additional shares by the Delivery Date, the Company shall be liable to the Investors and/or their assignees for a penalty equal to 1.5% of the aggregate Purchase Price
adjustment (in each instance to such Investor or its assignees pro rata in accordance with its participation in this offering) per 30-day period or pro rata for any portion thereof following the Delivery Date until 

  

 -21- 








 
the delivery of the additional shares, payable in Common Stock or cash, at the election of each Investor and/or its assignees. For this purpose, each share
of Common Stock shall be deemed to have a value equal to the arithmetic mean of the Market Price (as defined in the Warrants) for the ten (10) trading days beginning twenty (20) trading days prior to the issuance of such shares. 
  
 (d) The Company shall not enter into any agreement, arrangement or
understanding, take or refrain from taking any action or suffer to exist any circumstances that, in any such case, would result in the transactions contemplated by the Transaction Documents becoming subject to stockholder approval under Nasdaq
Marketplace Rule 4350(i) unless and until the Company first obtains such stockholder approval. 
  
 8. Survival and Indemnification. 
  
 8.1 Survival. The representations, warranties, covenants and agreements contained in this Agreement shall survive the Closing of the transactions contemplated by this Agreement. 
  
 8.2 Indemnification. The Company agrees to indemnify and hold harmless
each Investor and its Affiliates and their respective directors, officers, employees and agents from and against any and all losses, claims, damages, liabilities and expenses (including without limitation reasonable attorney fees and disbursements
and other expenses incurred in connection with investigating, preparing or defending any action, claim or proceeding, pending or threatened and the costs of enforcement thereof) (collectively, “Losses”) to which such Person may become
subject as a result of any breach of representation, warranty, covenant or agreement made by or to be performed on the part of the Company under the Transaction Documents, and will reimburse any such Person for all such amounts as they are incurred
by such Person. 
  
 8.3 Conduct of Indemnification
Proceedings. Promptly after receipt by any Person (the “Indemnified Person”) of notice of any demand, claim or circumstances which would or might give rise to a claim or the commencement of any action, proceeding
or investigation in respect of which indemnity may be sought pursuant to Section 8.2, such Indemnified Person shall promptly notify the Company in writing and the Company shall assume the defense thereof, including the employment of counsel
reasonably satisfactory to such Indemnified Person, and shall assume the payment of all fees and expenses; provided, however, that the failure of any Indemnified Person so to notify the Company shall not relieve the Company of its
obligations hereunder except to the extent that the Company is materially prejudiced by such failure to notify. In any such proceeding, any Indemnified Person shall have the right to retain its own counsel, but the fees and expenses of such counsel
shall be at the expense of such Indemnified Person unless: (i) the Company and the Indemnified Person shall have mutually agreed to the retention of such counsel; or (ii) in the reasonable judgment of counsel to such Indemnified Person
representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them. The Company shall not be liable for any settlement of any proceeding effected without its written consent, which
consent shall not be unreasonably withheld, but if settled with such consent, or if there be a final judgment for the plaintiff, the Company shall indemnify and hold harmless such Indemnified Person from and against any loss or liability (to the
extent stated above) by reason of such 

  

 -22- 








 
settlement or judgment. Without the prior written consent of the Indemnified Person, which consent shall not be unreasonably withheld, the Company shall not
effect any settlement of any pending or threatened proceeding in respect of which any Indemnified Person is or could have been a party and indemnity could have been sought hereunder by such Indemnified Party, unless such settlement includes an
unconditional release of such Indemnified Person from all liability arising out of such proceeding. 
  
 9. Miscellaneous. 
  
 9.1 Successors and Assigns. This Agreement may not be assigned by a party hereto without the prior written consent of the Company or the Investors,
as applicable, provided, however, that an Investor may assign its rights and delegate its duties hereunder in whole or in part to an Affiliate or to a third party acquiring some or all of its Securities in a private transaction without the prior
written consent of the Company or the other Investors, after notice duly given by such Investor to the Company provided, that no such assignment or obligation shall affect the obligations of such Investor hereunder. The provisions of this Agreement
shall inure to the benefit of and be binding upon the respective permitted successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective
successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 
  

9.2 Counterparts; Faxes. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. This Agreement may also be executed via facsimile, which shall be deemed an original. 
  
 9.3 Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing
or interpreting this Agreement. 
  
 9.4 Notices. Unless
otherwise provided, any notice required or permitted under this Agreement shall be given in writing and shall be deemed effectively given as hereinafter described (i) if given by personal delivery, then such notice shall be deemed given upon such
delivery, (ii) if given by telex or telecopier, then such notice shall be deemed given upon receipt of confirmation of complete transmittal, (iii) if given by mail, then such notice shall be deemed given upon the earlier of (A) receipt of such
notice by the recipient or (B) three days after such notice is deposited in first class mail, postage prepaid, and (iv) if given by an internationally recognized overnight air courier, then such notice shall be deemed given one Business Day after
delivery to such carrier. All notices shall be addressed to the party to be notified at the address as follows, or at such other address as such party may designate by ten days’ advance written notice to the other party: 
  
 If to the Company: 
  
 Tut Systems, Inc. 
 6000 SW Meadows Drive, Suite 200 
 Lake Oswego, Oregon 97035 
 Attention: Chief Financial Officer (Randy Gausman) 

Fax: 971.217.0458 
  

 -23- 








 With a copy to: 
  
 DLA Piper Rudnick Gray Cary US LLP 
 4365 Executive Drive, Suite 1100 
 San Diego, CA 92121 
 Attention: Marty B. Lorenzo, Esq. 
 Fax: 858.677.1401 
  
 If to the Investors: 
  
 to the addresses set forth on the signature pages hereto. 
  
 9.5 Expenses. The parties hereto shall pay their own costs and expenses in connection herewith, except that the Company shall pay the reasonable
fees and expenses of Lowenstein Sandler PC not to exceed $30,000. Such expenses shall be paid not later than the Closing. The Company shall reimburse the Investors upon demand for all reasonable out-of-pocket expenses incurred by the Investors,
including without limitation reimbursement of attorneys’ fees and disbursements, in connection with any amendment, modification or waiver of this Agreement or the other Transaction Documents. In the event that legal proceedings are commenced by
any party to this Agreement against another party to this Agreement in connection with this Agreement or the other Transaction Documents, the party or parties which do not prevail in such proceedings shall severally, but not jointly, pay their pro
rata share of the reasonable attorneys’ fees and other reasonable out-of-pocket costs and expenses incurred by the prevailing party in such proceedings. 
  
 9.6 Amendments and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either
generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company and the Investors. Any amendment or waiver effected in accordance with this paragraph shall be binding upon each holder of
any Securities purchased under this Agreement at the time outstanding, each future holder of all such Securities, and the Company. 
  
 9.7 Publicity. Except as set forth below, no public release or announcement concerning the transactions contemplated hereby shall be issued by the
Company or the Investors without the prior consent of the Company (in the case of a release or announcement by the Investors) or the Investors (in the case of a release or announcement by the Company) (which consents shall not be unreasonably
withheld), except as such release or announcement may be required by law or the applicable rules or regulations of any securities exchange or securities market, in which case the Company or the Investors, as the case may be, shall allow the
Investors or the Company, as applicable, to the extent reasonably practicable in the circumstances, reasonable time to comment on such release or announcement in advance of such issuance. By 

  

 -24- 








 
8:30 a.m. (New York City time) on the trading day immediately following the Closing Date, the Company shall issue a press release disclosing the consummation
of the transactions contemplated by this Agreement. No later than the third trading day following the Closing Date, the Company will file a Current Report on Form 8-K attaching the press release described in the foregoing sentence as well as copies
of the Transaction Documents. In addition, the Company will make such other filings and notices in the manner and time required by the SEC or Nasdaq. Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Investor, or
include the name of any Investor in any filing with the SEC (other than the Registration Statement and any exhibits to filings made in respect of this transaction in accordance with periodic filing requirements under the 1934 Act) or any regulatory
agency or Nasdaq, without the prior written consent of such Investor, except to the extent such disclosure is required by law or trading market regulations, in which case the Company shall provide the Investors with prior notice of such disclosure.

  
 9.8 Severability. Any provision of this Agreement that
is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof but shall be interpreted as if it were
written so as to be enforceable to the maximum extent permitted by applicable law, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. To the extent
permitted by applicable law, the parties hereby waive any provision of law which renders any provision hereof prohibited or unenforceable in any respect. 
  
 9.9 Entire Agreement. This Agreement, including the Exhibits, and the other Transaction Documents constitute the entire agreement among the parties
hereof with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, both oral and written, between the parties with respect to the subject matter hereof and thereof. 
  
 9.10 Further Assurances. The parties shall execute and deliver all
such further instruments and documents and take all such other actions as may reasonably be required to carry out the transactions contemplated hereby and to evidence the fulfillment of the agreements herein contained. 
  
 9.11 Governing Law; Consent to Jurisdiction; Waiver of Jury Trial.
This Agreement shall be governed by, and construed in accordance with, the internal laws of the State of New York without regard to the choice of law principles thereof. Each of the parties hereto irrevocably submits to the exclusive jurisdiction of
the courts of the State of New York located in New York County and the United States District Court for the Southern District of New York for the purpose of any suit, action, proceeding or judgment relating to or arising out of this Agreement and
the transactions contemplated hereby. Service of process in connection with any such suit, action or proceeding may be served on each party hereto by the same methods as are specified for the giving of notices under this Agreement. Each of the
parties hereto irrevocably consents to the jurisdiction of any such court in any such suit, action or proceeding and to the laying of venue in such court. Each party hereto irrevocably waives any objection to the laying of venue of any such suit,
action or proceeding brought in such courts and irrevocably waives any claim that any such suit, action or proceeding brought in any such court has been brought in 

  

 -25- 








 
an inconvenient forum. EACH OF THE PARTIES HERETO WAIVES ANY RIGHT TO REQUEST A TRIAL BY JURY IN ANY LITIGATION WITH RESPECT TO THIS AGREEMENT AND
REPRESENTS THAT COUNSEL HAS BEEN CONSULTED SPECIFICALLY AS TO THIS WAIVER. 
  
 9.12 Independent Nature of Investors’ Obligations and Rights. The obligations of each Investor under any Transaction Document are several and not joint with the obligations of any other Investor, and no
Investor shall be responsible in any way for the performance of the obligations of any other Investor under any Transaction Document. The decision of each Investor to purchase Securities pursuant to the Transaction Documents has been made by such
Investor independently of any other Investor. Nothing contained herein or in any Transaction Document, and no action taken by any Investor pursuant thereto, shall be deemed to constitute the Investors as a partnership, an association, a joint
venture or any other kind of entity, or create a presumption that the Investors are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Investor acknowledges
that no other Investor has acted as agent for such Investor in connection with making its investment hereunder and that no Investor will be acting as agent of such Investor in connection with monitoring its investment in the Securities or enforcing
its rights under the Transaction Documents. Each Investor shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out of this Agreement or out of the other Transaction Documents, and it
shall not be necessary for any other Investor to be joined as an additional party in any proceeding for such purpose. The Company acknowledges that each of the Investors has been provided with the same Transaction Documents for the purpose of
closing a transaction with multiple Investors and not because it was required or requested to do so by any Investor. 
  
 [signature page follows] 
  

 -26- 








 IN WITNESS WHEREOF, the parties have executed this Agreement or caused their duly authorized officers to
execute this Agreement as of the date first above written. 
  

					
	 The Company:
	 	TUT SYSTEMS, INC.
			
	 	 	By:	 	  


	 	 	Name:	 	 
	 	 	Title:	 	 

  

 -27- 









					
	 The Investors:
	 	SPECIAL SITUATIONS FUND III, L.P.
			
	 	 	By:	 	  


	 	 	Name:	 	David Greenhouse
	 	 	Title:	 	General Partner

  
 Aggregate Purchase Price: $3,975,800

 Number of Shares: 1,472,518 
 Number of Warrants: 736,259

  
 Address for Notice: 
  
 153 E. 53rd Street 
 55th Floor 
 New York, NY 10022 
  
 with a copy to:

  
 Lowenstein Sandler PC 
 65 Livingston Avenue 
 Roseland, NJ 07068 
 Attn: John D. Hogoboom, Esq. 
 Telephone:    973.597.2500 
 Facsimile:     973.597.2400 
  

					
	 	 	 SPECIAL SITUATIONS PRIVATE EQUITY FUND, L.P.

			
	 	 	 By:
	 	  


	 	 	 Name:
	 	David Greenhouse
	 	 	 Title:
	 	General Partner

  
 Aggregate Purchase Price: $845,000

 Number of Shares: 312,962 
 Number of Warrants: 156,481

  
 153 E. 53rd Street 
 55th Floor 
 New York, NY 10022 
  

 -28- 








 with a copy to: 
  
 Lowenstein Sandler PC 
 65 Livingston Avenue 
 Roseland, NJ 07068 
 Attn: John D. Hogoboom, Esq. 
 Telephone:    973.597.2500 
 Facsimile:     973.597.2400 
  

					
	 	 	SPECIAL SITUATIONS TECHNOLOGY FUND, L.P.
			
	 	 	By:	 	  


	 	 	Name:	 	David Greenhouse
	 	 	Title:	 	General Partner

  
 Aggregate Purchase Price: $161,000

 Number of Shares: 59,629 
 Number of Warrants: 29,814

  
 Address for Notice: 
  
 153 E. 53rd Street 
 55th Floor 
 New York, NY 10022 
  
 with a copy to:

  
 Lowenstein Sandler PC 
 65 Livingston Avenue 
 Roseland, NJ 07068 
 Attn: John D. Hogoboom, Esq. 
 Telephone:    973.597.2500 
 Facsimile:     973.597.2400 
  

					
	 	 	SPECIAL SITUATIONS TECHNOLOGY FUND II, L.P.
			
	 	 	 By:
	 	  


	 	 	 Name:
	 	David Greenhouse
	 	 	 Title:
	 	General Partner

  
 Aggregate Purchase Price: $996,000

 Number of Shares: 368,888 
 Number of Warrants: 184,444

  

 -29- 








 Address for Notice: 
  
 153 E. 53rd Street 
 55th Floor 
 New York, NY 10022 
  
 with a copy to: 
  
 Lowenstein Sandler PC 
 65 Livingston Avenue 
 Roseland, NJ 07068 
 Attn: John D. Hogoboom, Esq. 
 Telephone:    973.597.2500 
 Facsimile:     973.597.2400 
  

 -30- 









					
	 	 	 SRB GREENWAY CAPITAL, L.P.

			
	 	 	 By:
	 	SRB Management, L.P., General Partner
			
	 	 	 By:
	 	BC Advisors, L.L.C., General Partner
			
	 	 	 By:
	 	  


	 	 	 Name:
	 	Steven R. Becker
	 	 	 Title:
	 	Member

  
 Aggregate Purchase Price: $214,100

 Number of Shares: 79,296 
 Number of Warrants: 39,648

  
 Address for Notice: 
  
 300 Crescent Court, Suite 1111 
 Dallas, Texas 75201 
  
 with a copy to: 
  
 Lowenstein Sandler PC 
 65 Livingston Avenue 
 Roseland, NJ 07068 
 Attn: John D. Hogoboom, Esq. 
 Telephone:    973.597.2500 
 Facsimile:     973.597.2400 
  

					
	 	 	SRB GREENWAY CAPITAL (Q.P.), L.P.
			
	 	 	 By:
	 	SRB Management, L.P., General Partner
			
	 	 	 By:
	 	BC Advisors, L.L.C., General Partner
			
	 	 	 By:
	 	  


	 	 	 Name:
	 	Steven R. Becker
	 	 	 Title:
	 	Member

  
 Aggregate Purchase Price: $1,643,500

 Number of Shares: 608,703 
 Number of Warrants: 304,351

  

 -31- 








 Address for Notice: 
  
 300 Crescent Court, Suite 1111 
 Dallas, Texas 75201 
  
 with a copy to: 
  
 Lowenstein Sandler
PC 
 65 Livingston Avenue 
 Roseland, NJ 07068 
 Attn: John D. Hogoboom, Esq. 
 Telephone:    973.597.2500 
 Facsimile:     973.597.2400 
  

					
	 	 	 SRB GREENWAY OFFSHORE

	 	 	 OPERATING FUND, L.P.

			
	 	 	 By:
	 	SRB Management, L.P., General Partner
	 	 	 By:
	 	BC Advisors, L.L.C., General Partner
			
	 	 	 By:
	 	  


	 	 	 Name:
	 	Steven R. Becker
	 	 	 Title:
	 	Member

  
 Aggregate Purchase Price: $135,000

 Number of Shares: 50,000 
 Number of Warrants: 25,000

  
 Address for Notice: 
  
 300 Crescent Court, Suite 1111 
 Dallas, Texas 75201 
  
 with a copy to: 
  
 Lowenstein Sandler PC 
 65 Livingston Avenue 
 Roseland, NJ 07068 
 Attn: John D. Hogoboom, Esq. 
 Telephone:    973.597.2500 
 Facsimile:     973.597.2400 
  

 -32- 









					
	 	 	 WALKER SMITH INTERNATIONAL FUND, LTD.

			
	 	 	 By:
	 	WS Capital Management, L.P., Attorney-in-Fact
			
	 	 	 By:
	 	WS Capital, L.L.C., General Partner
			
	 	 	 By:
	 	  


	 	 	 Name:
	 	 
	 	 	 Title:
	 	Member

  
 Aggregate Purchase Price: $881,600

 Number of Shares: 326,518 
 Number of Warrants: 163,259

  
 Address for Notice: 
  
 300 Crescent Court, Suite 1111 
 Dallas, Texas 75201 
  
 with a copy to: 
  
 Lowenstein Sandler PC 
 65 Livingston Avenue 
 Roseland, NJ 07068 
 Attn: John D. Hogoboom, Esq. 
 Telephone:    973.597.2500 
 Facsimile:     973.597.2400 
  

					
	 	 	 WALKER SMITH CAPITAL (Q.P.), L.P.

			
	 	 	 By:
	 	WS Capital Management, L.P., General Partner
			
	 	 	 By:
	 	WS Capital, L.L.C., General Partner
			
	 	 	 By:
	 	  


	 	 	 Name:
	 	 
	 	 	 Title:
	 	Member

  
 Aggregate Purchase Price: $111,400

 Number of Shares: 41,259 
 Number of Warrants: 20,629

  

 -33- 








 Address for Notice: 
  
 300 Crescent Court, Suite 1111 
 Dallas, Texas 75201 
  
 with a copy to: 
  
 Lowenstein Sandler
PC 
 65 Livingston Avenue 
 Roseland, NJ 07068 
 Attn: John D. Hogoboom, Esq. 
 Telephone:    973.597.2500 
 Facsimile:     973.597.2400 
  

					
	 	 	WALKER SMITH CAPITAL, L.P.
			
	 	 	By:	 	WS Capital Management, L.P., General Partner
			
	 	 	By:	 	WS Capital, L.L.C., General Partner
			
	 	 	By:	 	  


	 	 	Name:	 	 
	 	 	Title:	 	Member

  
 Aggregate Purchase Price: $627,300

 Number of Shares: 232,333 
 Number of Warrants: 116,166

  
 Address for Notice: 
  
 300 Crescent Court, Suite 1111 
 Dallas, Texas 75201 
  

 -34- 








 with a copy to: 
  
 Lowenstein Sandler PC 
 65 Livingston Avenue 
 Roseland, NJ 07068 
 Attn: John D. Hogoboom, Esq. 
 Telephone:    973.597.2500 
 Facsimile:     973.597.2400 
  

					
	 	 	 WS OPPORTUNITY FUND INTERNATIONAL, LTD.

			
	 	 	 By:
	 	WS Ventures Management, L.P., Attorney-in-Fact
			
	 	 	 By:
	 	WSV Management, L.L.C., General Partner
			
	 	 	 By:
	 	  


	 	 	 Name:
	 	 
	 	 	 Title:
	 	Member

  
 Aggregate Purchase Price: $154,700

 Number of Shares: 57,296 
 Number of Warrants: 28,648

  
 Address for Notice: 
  
 300 Crescent Court, Suite 1111 
 Dallas, Texas 75201 
  

 -35- 








 with a copy to: 
  
 Lowenstein Sandler PC 
 65 Livingston Avenue 
 Roseland, NJ 07068 
 Attn: John D. Hogoboom, Esq. 
 Telephone:    973.597.2500 
 Facsimile:     973.597.2400 
  

					
	 	 	 WS OPPORTUNITY FUND, L.P.

			
	 	 	 By:
	 	WS Ventures Management, L.P., General Partner
			
	 	 	 By:
	 	WSV Management, L.L.C., General Partner
			
	 	 	 By:
	 	  


	 	 	 Name:
	 	 
	 	 	 Title:
	 	Member

  
 Aggregate Purchase Price: $109,600

 Number of Shares: 40,592 
 Number of Warrants: 20,296

  
 Address for Notice: 
  
 300 Crescent Court, Suite 1111 
 Dallas, Texas 75201 
  

 -36- 








 with a copy to: 
  
 Lowenstein Sandler PC 
 65 Livingston Avenue 
 Roseland, NJ 07068 
 Attn: John D. Hogoboom, Esq. 
 Telephone:    973.597.2500 
 Facsimile:     973.597.2400 
  

					
	 	 	 WS OPPORTUNITY FUND (Q.P.), L.P.

			
	 	 	 By:
	 	WS Ventures Management, L.P., General Partner
			
	 	 	 By:
	 	WSV Management, L.L.C., General Partner
			
	 	 	 By:
	 	  


	 	 	 Name:
	 	 
	 	 	 Title:
	 	Member

  
 Aggregate Purchase Price: $108,000

 Number of Shares: 40,000 
 Number of Warrants: 20,000

  
 Address for Notice: 
  
 300 Crescent Court, Suite 1111 
 Dallas, Texas 75201 
  
 with a copy to: 
  
 Lowenstein Sandler PC 
 65 Livingston Avenue 
 Roseland, NJ 07068 
 Attn: John D. Hogoboom, Esq. 
 Telephone:    973.597.2500 
 Facsimile:     973.597.2400 
  
 [other investors] 
  

 -37-